ChemPartner’s Drug Metabolism Pharmacokinetic (DMPK) & Exploratory Toxicology department consists of bioanalytical (GLP- and non-GLP), in vitro ADME, pharmacokinetics and toxicology groups. Our leadership team, drawing on experiences from world-renowned pharma companies, emphasizes a science-based culture and the execution of quality DMPK/toxicology studies as well as the integration of DMPK/toxicology data into our pharma and biotech partners’ discovery programs. ChemPartner also conducts studies for many biopharmaceutical clients in support of regulatory filings.
Over the past decade, extensive ADME profiling (80,000+), PK, and exploratory toxicology studies (10,000+) have been conducted to support numerous drug discovery and development programs. Working closely with our internal cell biology, pharmacology, and antibody engineering departments, ChemPartner’s DMPK group supports translational medicine through our expertise in formulation development, in vitro–in vivo extrapolation, PK/PD modeling, biomarker analysis, and metabolomics. We take pride in our work and view our partners’ success as our success.